Regeneron Stock Analysis


USD 613.61  1.35  0.22%   

The latest indifference towards the small price fluctuations of Regeneron Pharmaceuticals created some momentum for institutional investors as it was traded today as low as 606.96 and as high as 621.63 per share. The company management teams did not add any value to Regeneron Pharmaceuticals investors in July. However, most investors can still diversify their portfolios with Regeneron Pharmaceuticals to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.0. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Additionally, take a look at Your Equity Center.
The Regeneron Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Regeneron Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Regeneron Stock analysis module also helps to analyze the Regeneron Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Regeneron Stock Analysis Notes

About 88.0% of the company shares are owned by institutional investors. The book value of Regeneron Pharmaceuticals was at this time reported as 185.41. The company recorded earning per share (EPS) of 69.88. Regeneron Pharmaceuticals had not issued any dividends in recent years. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people. To find out more about Regeneron Pharmaceuticals contact Leonard Schleifer at 914 847-7000 or learn more at

Regeneron Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Regeneron Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Regeneron Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Regeneron Pharmaceuticals has a strong financial position based on the latest SEC filings
Over 88.0% of the company shares are owned by institutional investors
Latest headline from Phio Pharmaceuticals versus Regeneron Pharmaceuticals Critical Analysis - Defense World

Regeneron Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Regeneron Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regeneron Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End4th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Regeneron Largest EPS Surprises

Earnings surprises can significantly impact Regeneron Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Regeneron Pharmaceuticals Thematic Classifications

In addition to having Regeneron Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer
Biotechnology and pharmaceuticals production and services

Regeneron Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Sumitomo Mitsui Trust Holdings IncCommon Shares399.3 K236.1 M
Candriam ScaCommon Shares372.8 K220.4 M
New York State Common Retirement FundCommon Shares194.3 K114.9 M
Handelsbanken Fonder AbCommon Shares194.3 K114.9 M
Dekabank Deutsche GirozentraleCommon Shares171.2 K102 M
Mcdonald Capital Investors IncCommon Shares164.1 K97 M
Russell Investments Group LtdCommon Shares160.6 K95.2 M
Note, although Regeneron Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Regeneron Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 63.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regeneron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Regeneron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Regeneron Profitablity

Regeneron Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Regeneron Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Regeneron Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Regeneron Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Regeneron Pharmaceuticals' profitability requires more research than a typical breakdown of Regeneron Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 48.06 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 57.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.57.
Last ReportedProjected for 2022
Return on Investment 51.91  56.00 
Return on Average Assets 37.91  40.91 
Return on Average Equity 54.21  58.49 
Return on Invested Capital 0.23  0.25 
Return on Sales 0.25  0.27 

Management Efficiency

The entity has return on total asset (ROA) of 25.84 % which means that it generated profit of $25.84 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 49.75 %, meaning that it created $49.75 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals management efficiency ratios could be used to measure how well regeneron pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is expected to rise to 56.00 this year. Return on Average Assets is expected to rise to 40.91 this year. Regeneron Pharmaceuticals Return on Average Assets are quite stable at the moment as compared to the past year. The company's current value of Return on Average Assets is estimated at 40.91. Tangible Assets Book Value per Share is expected to rise to 64.42 this year, although the value of Revenue to Assets will most likely fall to 0.59.
Last ReportedProjected for 2022
Book Value per Share 38.09  41.10 
Enterprise Value over EBIT 25.20  27.19 
Enterprise Value over EBITDA 23.83  25.71 
Price to Book Value 7.83  7.47 
Tangible Assets Book Value per Share 59.71  64.42 
Enterprise Value34.4 B37.1 B
Tangible Asset Value6.3 B6.8 B

Technical Drivers

As of the 7th of August, Regeneron Pharmaceuticals holds the risk adjusted performance of (0.06), and Coefficient Of Variation of (2,316). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regeneron Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Regeneron Pharmaceuticals, which can be compared to its competitors. Please check Regeneron Pharmaceuticals downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Regeneron Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 613.61 per share. Given that Regeneron Pharmaceuticals has jensen alpha of (0.09), we recommend you to check out Regeneron Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Regeneron Pharmaceuticals Price Movement Analysis

The output start index for this execution was fifty-seven with a total number of output elements of four. Regeneron Pharmaceuticals Triple Exponential Moving Average indicator shows smoothing effect of Regeneron Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Regeneron Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marion McCourt few days ago via Macroaxis 
Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Marion McCourt over a month ago via Macroaxis 
Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Marion McCourt over two months ago via Macroaxis 
Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Murphy Andrew J over two months ago via Macroaxis 
Sale by Murphy Andrew J of tradable shares of Regeneron Pharmaceuticals
Murphy Andrew J over two months ago via Macroaxis 
Sale by Murphy Andrew J of 352 shares of Regeneron Pharmaceuticals
Murphy Andrew J over three months ago via Macroaxis 
Sale by Murphy Andrew J of 465 shares of Regeneron Pharmaceuticals
Christopher Fenimore over three months ago via Macroaxis 
Exercise or conversion by Christopher Fenimore of 2450 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Leonard Schleifer over three months ago via Macroaxis 
Regeneron Pharmaceuticals exotic insider transaction detected
Robert Landry over three months ago via Macroaxis 
Exercise or conversion by Robert Landry of 1500 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Michael Brown over three months ago via Macroaxis 
Exercise or conversion by Michael Brown of 408 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Robert Landry over three months ago via Macroaxis 
Exercise or conversion by Robert Landry of 400 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Huda Zoghbi over three months ago via Macroaxis 
Exercise or conversion by Huda Zoghbi of 2000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Regeneron Pharmaceuticals Outstanding Bonds

Regeneron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regeneron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regeneron bonds can be classified according to their maturity, which is the date when Regeneron Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Regeneron Pharmaceuticals Predictive Daily Indicators

Regeneron Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regeneron Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Regeneron Pharmaceuticals Forecast Models

Regeneron Pharmaceuticals time-series forecasting models is one of many Regeneron Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Regeneron Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Regeneron Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Regeneron Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Regeneron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Regeneron Pharmaceuticals. By using and applying Regeneron Stock analysis, traders can create a robust methodology for identifying Regeneron entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 55.67  60.06 
EBITDA Margin 60.13  64.88 
Gross Margin 84.83  98.23 
Profit Margin 50.25  54.21 
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people.

Current Regeneron Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Regeneron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Regeneron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Regeneron Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Regeneron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Regeneron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Regeneron Pharmaceuticals, talking to its executives and customers, or listening to Regeneron conference calls.
Regeneron Analyst Advice Details

Regeneron Stock Analysis Indicators

Regeneron Pharmaceuticals stock analysis indicators help investors evaluate how Regeneron Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Regeneron Pharmaceuticals shares will generate the highest return on investment. By understating and applying Regeneron Pharmaceuticals stock analysis, traders can identify Regeneron Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio3.95
Fifty Two Week Low538.01
Revenue Growth17.30%
Average Daily Volume Last 10 Day532.16k
Shares Short Prior Month2.58M
Average Daily Volume In Three Month670.11k
Earnings Growth-14.70%
Shares Percent Shares Out2.60%
Earnings Quarterly Growth-12.70%
Gross Margins66.42%
Forward Price Earnings13.28
Short Percent Of Float2.76%
Float Shares103.13M
Fifty Two Week High747.42
Fifty Day Average607.91
Enterprise Value To Ebitda6.14
Two Hundred Day Average632.07
Enterprise Value To Revenue3.50
Additionally, take a look at Your Equity Center. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
65.7 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.